Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Drugs Acting on Autonomic Ganglia: Blockers

Drugs Acting on Autonomic Ganglia: Blockers

Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Training Pathways to Academic Neuro-Ophthalmology: A Comparative Study of Ophthalmology and Neurology Residencies.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society·2025

Same author

A Review of Program Signaling Effects, Perceptions, and Trends for Medical Residencies.

Journal of graduate medical education·2025

Same author

Primary Visual Pathway Changes in Individuals With Chronic Mild Traumatic Brain Injury.

JAMA ophthalmology·2024

Same author

Unilateral vascular abnormality: A case of peripheral retinal arteriolar tortuosity associated with a prepapillary vascular loop.

American journal of ophthalmology case reports·2020

Same author

Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack.

Journal of the neurological sciences·2020

Same author

Part I. SARS-CoV-2 triggered 'PANIC' attack in severe COVID-19.

Journal of the neurological sciences·2020

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Current pharmacologic testing for Horner syndrome.

Mansoor Mughal¹, Reid Longmuir

¹The University of Iowa Hospitals and Clinics, Department of Ophthalmology and Visual Sciences, IA 52242, USA.

Current Neurology and Neuroscience Reports

|August 12, 2009

Summary

Horner syndrome diagnosis involves testing the oculosympathetic pathway. While apraclonidine testing is an alternative, concerns exist about its accuracy and safety in children.

Area of Science:

Ophthalmology
Neurology

Background:

Horner syndrome, first described in 1727, results from damage to the oculosympathetic pathway.
Diagnosis traditionally involves pharmacologic testing, including cocaine and hydroxyamphetamine localization.

Purpose of the Study:

To evaluate apraclonidine testing as an alternative diagnostic method for Horner syndrome.
To address concerns regarding potential false-negative results and safety in pediatric patients.

Main Methods:

Review of diagnostic protocols for Horner syndrome.
Analysis of apraclonidine testing efficacy and safety data.

Main Results:

Apraclonidine testing is a more recent alternative to traditional pharmacologic agents.

More Related Videos

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Related Experiment Videos

Last Updated: Jun 21, 2026

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Potential for false-negative results with apraclonidine testing has been noted.

Safety concerns regarding apraclonidine use in young children warrant consideration.

Conclusions:

Apraclonidine testing offers a potential alternative for diagnosing Horner syndrome.
Further investigation is needed to confirm its reliability and safety, especially in pediatric populations.